{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:45:07Z","timestamp":1774489507522,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>(Pre\u2010)clinical studies have not ruled out a potential risk of second primary cancer (SCP) under the effect of some new androgen receptor pathway inhibitors (ARPIs), especially enzalutamide (ENZ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the French health reimbursement claims database (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9), we designed a case\u2013control study nested in a 2013\u20132020 cohort of new users of androgen\u2010deprivation therapy. The cases were patients with a first diagnosis of SPC, identified beyond 12\u2009months following cohort entry and up to December 31st<jats:sup>,<\/jats:sup> 2021; up to 10 controls were matched per case, based on age and cohort entry date. The main analysis focused on patients who had not switched to a different ARPI. Applying a one\u2010year lag time, we determined the most frequent and longest cumulative exposure patterns to abiraterone (ABI) or ENZ and estimated the odds ratios.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort comprised 147\u2009092 patients, including 7928 cases and 78\u2009554 controls eligible for analysis. The SPCs mainly involve the digestive organs, the urinary tract, or the lungs. Recent and short exposure to ENZ was associated with SPC: OR 1.7, 95% CI [1.2\u20132.4]. Recent one full year of exposure to ABI, as well as full\u2010year plus part of the second year, was associated with SPC: OR 1.8 [1.2\u20132.7] and 2.3 [1.3\u20134.0], respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion\/Conclusion<\/jats:title><jats:p>SPC cases were mainly observed among recently exposed patients, which could be linked to a detection bias. The insufficient number of patients exposed over many years means that no definitive conclusions can be drawn.<\/jats:p><\/jats:sec>","DOI":"10.1111\/fcp.70004","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T23:34:11Z","timestamp":1742254451000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second primary cancers and hormonal therapies for prostate cancer: A nested case\u2013control study"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-9107","authenticated-orcid":false,"given":"Lucie\u2010Marie","family":"Scailteux","sequence":"first","affiliation":[{"name":"Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail) \u2010 UMR_S 1085  Rennes France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale, CHU Bordeaux ; Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Inserm, DRUGS\u2010SAFE National Platform of Pharmacoepidemiology University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Gundelwein","sequence":"additional","affiliation":[{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CLCC Eug\u00e8ne Marquis, COSS (Chemistry Oncogenesis Signaling) INSERM, University Rennes  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[{"name":"Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail) \u2010 UMR_S 1085  Rennes France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Balusson","sequence":"additional","affiliation":[{"name":"Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail) \u2010 UMR_S 1085  Rennes France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale, CHU Bordeaux ; Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Inserm, DRUGS\u2010SAFE National Platform of Pharmacoepidemiology University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"EAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010ISUP\u2010SIOG\u2010Guidelines\u2010on\u2010Prostate\u2010Cancer\u20102023_2023\u201006\u201013\u2010141145.pdf. Accessed January 9 2024.https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full\u2010guideline\/EAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010ISUP\u2010SIOG\u2010Guidelines\u2010on\u2010Prostate\u2010Cancer\u20102023_2023\u201006\u201013\u2010141145.pdf"},{"key":"e_1_2_12_3_1","unstructured":"Xtandi \u2010 Risk management plan(last update 05\/12\/2023). Accessed July 19 2024.https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/xtandi-epar-risk-management-plan_en.pdf"},{"key":"e_1_2_12_4_1","unstructured":"Xtandi\u2010Assessment report\u2010procedureEMEA\/H\/C\/002639\/II\/0047\/G.2021. Accessed January 10 2024.https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/xtandi-h-c-2639-ii-0047-g-epar-assessment-report-variation_en.pdf"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2003892"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(23)00063\u20133"},{"key":"e_1_2_12_8_1","unstructured":"Xtandi product information (updated 01\/06\/2022). Accessed January 10 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf"},{"key":"e_1_2_12_9_1","unstructured":"Zytiga\u2010EMA Risk management plan (last update 06\/12\/2023). Accessed July 19 2024.https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/zytiga-epar-risk-management-plan_en.pdf"},{"key":"e_1_2_12_10_1","unstructured":"Nubeqa\u2010Asessment report\u2010 procedure EMEA\/H\/C\/004790\/II\/0009. Accessed February 7 2024.https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/nubeqa-h-c-4790-ii-0009-epar-assessment-report-variation_en.pdf"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0890\u20106238(96)00203\u20131"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262339402200211"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408449991349203"},{"key":"e_1_2_12_14_1","unstructured":"Erleada\u2010Product\u2010information (Updated 09\/01\/2024). Accessed February 7 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(12)70379\u20130"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.056"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.011"},{"key":"e_1_2_12_22_1","unstructured":"Nubeqa\u2010EMA risk management plan (updated 20\/03\/2023). Accessed February 7 2024.https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/nubeqa-epar-risk-management-plan-summary_en.pdf"},{"key":"e_1_2_12_23_1","unstructured":"Erleada\u2010EMA\u2010risk management plan (Updated 27\/09\/2023). Accessed February 7 2024.https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/erleada-epar-risk-management-plan-summary_en.pdf"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1764"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.23130"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102020\u20130315"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.01.009"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2023.05.004"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113189"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.12.012"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i851"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.23025"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6922"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5701"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5746"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006\u2010341x.2000.01105.x"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.01.021"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3701"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227552"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4387415"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.04.004"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14972"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2020.151047"},{"key":"e_1_2_12_45_1","unstructured":"Zytiga\u2010Product\u2010information (update 29 June 2022).pdf. Accessed February 5 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/zytiga\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/746769"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u2010410X.2009.08838.x"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01841"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa141"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa190"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010021\u201000318\u20103"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010022\u201000588\u20105"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:19:27Z","timestamp":1743319167000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/fcp.70004"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70004","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70004"}}